https://orcid.org/0000-0003-0870-2309
References
- Diagnostic and statistical manual of mental disorders (DSM-5®). Washington (DC): American Psychiatric Association; 2013 [cited 8 October 2021]. Available from: https://www.psychiatry.org/psychiatrists/practice/dsm.
- Global Burden of Disease Study Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743–800.
- Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. FOC. 2012;10(2):194–216.
- Vieta E. The role of long acting antipsychotics in bipolar disorder. Eur Psychiatr. 2017;41(S1):S15.
- Wang P, Si T. Use of antipsychotics in the treatment of depressive disorders. Shanghai Arch Psychiatry. 2013;25(3):134–140.
- Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161(8):1334–1349.
- Cornett EM, Novitch M, Kaye AD, et al. Medication-induced tardive dyskinesia: a review and update. Ochsner J. 2017;17(2):162–174.
- Savitt D, Jankovic J. Tardive syndromes. J Neurol Sci. 2018;389:35–42.
- McEvoy J, Gandhi SK, Rizio AA, et al. Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia. Qual Life Res. 2019;28(12):3303–3312.
- Caroff SN, Yeomans K, Lenderking WR, et al. RE-KINECT: a prospective study of the presence and healthcare burden of tardive dyskinesia in clinical practice settings. J Clin Psychopharmacol. 2020;40(3):259–268.
- Strassnig M, Rosenfeld A, Harvey PD. Tardive dyskinesia: motor system impairments, cognition and everyday functioning. CNS Spectr. 2018;23(6):370–377.
- Wu JQ, Chen DC, Xiu MH, et al. Tardive dyskinesia is associated with greater cognitive impairment in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2013;46:71–77.
- Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Washington (DC): American Psychiatric Association; 2021.
- Factor SA. Management of tardive syndrome: medications and surgical treatments. Neurotherapeutics. 2020;17(4):1694–1712.
- Lenert L, Morss S, Goldstein MK, et al. Measurement of the validity of utility elicitations performed by computerized interview. Med Care. 1997;35(9):915–920.
- Revicki DA, Hanlon J, Martin S, et al. Patient-based utilities for bipolar disorder-related health states. J Affect Disord. 2005;87(2–3):203–210.
- Lenert LA, Sturley AP, Rapaport MH, et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res. 2004;71(1):155–165.
- Bleichrodt H. A new explanation for the difference between time trade-off utilities and standard gamble utilities. Health Econ. 2002;11(5):447–456.
- van Osch SM, Wakker PP, van den Hout WB, et al. Correcting biases in standard gamble and time tradeoff utilities. Med Decis Making. 2004;24(5):511–517.
- Wright DR, Wittenberg E, Swan JS, et al. Methods for measuring temporary health states for cost-utility analyses. Pharmacoeconomics. 2009;27(9):713–723.
- Bleichrodt H, Johannesson M. Standard gamble, time trade-off and rating scale: experimental results on the ranking properties of QALYs. J Health Econ. 1997;16(2):155–175.
- Morss SE, Lenert LA, Faustman WO. The side effects of antipsychotic drugs and patients’ quality of life: patient education and preference assessment with computers and multimedia. Proc Annu Symp Comput Appl Med Care. 1993;17–21.